New hope for tough lung cancer? experimental drug IBI363 targets resistant tumors
NCT ID NCT07289048
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called IBI363 in 35 people with advanced small cell lung cancer that has worsened after at least two prior treatments, including immunotherapy. IBI363 is designed to boost the immune system's ability to attack cancer cells. The main goal is to see if the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI363 (a drug that combines PD-1 inhibition with IL-2 stimulation to boost immune response)
- What this could lead to
- If successful, this could offer a new treatment option for patients with advanced small cell lung cancer who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase study with only 35 participants and no comparison group. The drug may not shrink tumors or could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug combo outperform standard chemo for tough lung cancer?
- New drug cocktail aims to shrink tough lung cancers
- New drug cocktail aims at resistant lung cancer
- New drug combo aims to outperform standard care in aggressive lung cancer
- New hope for aggressive lung cancer: drug cocktail plus Low-Dose radiation shows promise
- New combo therapy targets tough lung cancer in early trial